Potential analysis and monitoring on the annual meeting 2011 presented the AACR benefits of circulating Microvesicles for early detection

CARIS life sciences, Inc., focus on life sciences leader allows precise and personalized healthcare by highest quality, anatomic pathology, molecular profiling and blood-based diagnostic services, this weekend presents key insights into the potential role of circulating Microvesicles (cMV) as a non-invasive blood based test technology at the American Association for cancer research (AACR) annual meeting. The potential of the cMV supports the data presented in the development of different blood-based diagnosis, prognosis and Theranostic tests, as well as for therapeutic response measurement. ™, developed by CARIS life sciences, under the brand of Carisome this is versatile blood-based technology for potential utility as a tool in the diagnosis of common cancers, including colon, breast cancer, lung cancer and prostate cancer, as well as other complex diseases studied.

A summary of each AACR poster presented the following:

"Subpopulations of circulating Microvesicles have different MicroRNA profiles," said the diagnosis, prognosis and Theranostic implications isolate tissue specific cMV populations of patients plasma due to surface protein composition associated with.

"Plasma of won circulating Microvesicles recognize and can help monitor breast cancer related diseases," showed that in addition to the support of the diagnosis, monitoring disturbed can offer specific subpopulations of cMV important biologic information processes of breast cancer.

"Enriching for rare subpopulations of circulating Microvesicles by the exhaustion of the endothelial and leukocyte-derived Microvesicles," suggested, a possible method for a complete characterization of biomarker-disease associated cells profiles associated with cMV derived.

"Detection of lung cancer of plasma with the Biosignature of the circulating Microvesicles," provided evidence first, that the identification of Biosignatures in different subpopulations of cMV a powerful blood approach for the detection and monitoring of specific disease States can offer.

"Comparison of me patterns in serum, plasma, cell line cMV," shown that isolated from peripheral blood of circulating Microvesicles offer a unique and potentially clinically relevant source of me for blood-based analysis.

"The importance of personalized medicine tools continues to grow, and we believe that the next challenge, commented Dr. Les Paul, Senior Vice President for research and development and Chief Technology Officer represented circulating Microvesicle research efforts by CARIS."This technology platform has the potential to identify disease-associated circulating Microvesicles in the blood, promise for clinical benefit in early diagnostic tests, disease monitoring and therapeutic response. "

CARIS life sciences Carisome technology offers the potential, healthcare with blood Diagnostics, sign and therapeutic guidance, the clinicians and their patients with treatment decisions constitute aid. CARIS work in this area contains great advances in the understanding of the cMV and their potential application to the treatment of patients with a more accurate diagnosis and therapeutic planning.

Source:
CARIS life sciences